This trial is conducted in the United States of America (USA). The aim of this trial is to evaluate the efficacy of activated recombinant human factor VII in treatment of bleeding in patients having undergone a hematopoietic stem cell transplantation.

Two days repeated treatment regimen - high dose administered i.v. (into the vein)

Eligibility

Ages Eligible for Study:

12 Years and older

Genders Eligible for Study:

Both

Accepts Healthy Volunteers:

No

Criteria

Inclusion Criteria:

Patients who have undergone a hematopoietic stem cell transplantation

Exclusion Criteria:

Known or suspected allergy to trial product

Participation in other trials with unapproved drugs or trials with equal or similar objective

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01564563